Protecting Patient Access to Cancer and Complex Therapies Act

Hozzl · 2025-07-30T08:05:27Z

Explore the details of House Bill 4299 Protecting Patient Access to Cancer and Complex Therapies Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on undefined. Stay informed on legislative developments.

7/30/2025, 8:05 AM

Summary of Bill HR 4299

H.R. 4299, introduced in the 119th Congress on July 7, 2025, aims to amend title XVIII of the Social Security Act to enable manufacturers to issue rebates for certain drugs and biological products that are under maximum fair price negotiation.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 4299

Bill HR 4299 is currently in the status of Bill Introduced since July 7, 2025. Bill HR 4299 was introduced during Congress 119 and was introduced to the House on July 7, 2025. Bill HR 4299's most recent activity was Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. as of July 7, 2025

Bipartisan Support of Bill HR 4299

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 4299

Primary Policy Focus

Alternate Title(s) of Bill HR 4299

To amend title XVIII of the Social Security Act to provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation.